Brineura: Uses, Dosage & Side Effects
An enzyme replacement therapy for neuronal ceroid lipofuscinosis type 2 (CLN2 disease), delivering recombinant TPP1 enzyme directly to the brain to slow neurological decline
Brineura (cerliponase alfa) is the first and only enzyme replacement therapy approved for neuronal ceroid lipofuscinosis type 2 (CLN2 disease), a rare and devastating lysosomal storage disorder. CLN2 disease, also known as TPP1 deficiency or late infantile neuronal ceroid lipofuscinosis, is an inherited neurodegenerative condition that typically manifests between ages 2 and 4 with seizures, progressive loss of motor skills, and decline in language ability. Brineura is administered directly into the cerebrospinal fluid via an intracerebroventricular access device every two weeks by trained healthcare professionals in a hospital setting. Clinical trials have demonstrated that Brineura significantly slows the loss of motor and language function compared to the natural disease course.
Quick Facts: Brineura
Key Takeaways
- Brineura is the first approved treatment specifically for CLN2 disease (TPP1 deficiency), a rare pediatric neurodegenerative disorder.
- The medication is administered directly into the brain ventricles through a surgically implanted access device every two weeks.
- Clinical studies show Brineura significantly slows the decline in motor and language function compared to the untreated disease course.
- Common side effects include seizures, fever, vomiting, hypersensitivity reactions, and device-related complications.
- Treatment requires careful monitoring for anaphylaxis, device-related infections, and changes in cerebrospinal fluid parameters.
What Is Brineura and What Is It Used For?
Brineura contains the active substance cerliponase alfa, which belongs to a group of medicines called enzyme replacement therapies (ERTs). It is specifically designed to treat patients with neuronal ceroid lipofuscinosis type 2 (CLN2 disease), also known as tripeptidyl peptidase 1 (TPP1) deficiency. CLN2 disease is one of a group of inherited neurological disorders collectively called Batten disease, or neuronal ceroid lipofuscinoses (NCLs).
People with CLN2 disease lack, or have insufficient amounts of, an enzyme called TPP1 (tripeptidyl peptidase 1). This enzyme normally functions within lysosomes, the cellular compartments responsible for breaking down waste materials. When TPP1 is absent or deficient, substances known as lysosomal storage materials (specifically ceroid and lipofuscin) accumulate in various parts of the body, particularly in the brain. This progressive accumulation leads to the destruction of nerve cells, causing severe and irreversible neurological damage.
CLN2 disease typically presents in children between the ages of 2 and 4 years. The earliest symptoms usually include the onset of seizures (epilepsy) that are often difficult to control with standard anti-seizure medications. This is followed by progressive loss of motor function (the ability to walk, stand, and coordinate movements), deterioration of language and cognitive abilities, and eventually loss of vision. Without treatment, most children with CLN2 disease experience rapid neurological decline, losing the ability to walk independently by approximately age 6 and becoming fully dependent on caregivers within a few years.
How Does Brineura Work?
Brineura replaces the missing TPP1 enzyme by providing a recombinant (laboratory-manufactured) form of human TPP1. By delivering the functional enzyme directly into the cerebrospinal fluid (the fluid surrounding the brain and spinal cord), Brineura helps reduce the accumulation of lysosomal storage materials in the brain. This enzyme replacement helps preserve neuronal function and slows the progression of neurological decline.
Because the TPP1 enzyme cannot cross the blood-brain barrier when given intravenously, Brineura must be administered directly into the fluid-filled ventricles of the brain (intracerebroventricular infusion). This unique route of administration ensures that the enzyme reaches the central nervous system where it is most needed. Once delivered into the cerebrospinal fluid, cerliponase alfa is taken up by neurons and other brain cells through a process called mannose-6-phosphate receptor-mediated endocytosis, entering the lysosomes where it performs its enzymatic function.
In the pivotal clinical trial, Brineura demonstrated a statistically significant reduction in the rate of decline in motor and language function compared to a matched untreated historical control group. Patients treated with Brineura showed substantially slower loss of walking ability and language skills, indicating that the therapy meaningfully alters the disease trajectory. Brineura received orphan drug designation in both the European Union and the United States, and was approved under exceptional circumstances owing to the rarity of CLN2 disease.
What Should You Know Before Receiving Brineura?
Contraindications
Brineura must not be used in the following situations:
- Life-threatening allergic reactions: If the patient has previously experienced life-threatening allergic reactions (anaphylaxis) to cerliponase alfa or any of the other ingredients in Brineura, and the reaction recurs upon re-administration, the medication must be discontinued permanently.
- Ventriculoperitoneal shunt: Patients who have an implanted shunt for draining excess cerebrospinal fluid from the brain (such as a ventriculoperitoneal shunt) must not receive Brineura, as the medication delivery system is incompatible with these drainage devices.
- Active device-related infection: Treatment must be postponed if the patient currently has signs of infection that may be related to the implanted intracerebroventricular access device, or if there are problems with the device itself. The physician may decide to resume treatment once the infection or device-related issues have been resolved.
Warnings and Precautions
Life-threatening anaphylactic reactions are possible with Brineura. Healthcare providers must be prepared to manage anaphylaxis during every infusion. Signs include hives, itching, flushing, swollen lips or tongue, chills, rapid heartbeat, breathing difficulties, hoarseness, cyanosis (blue discoloration around fingertips or lips), low muscle tone, fainting, diarrhea, or incontinence. Seek immediate medical attention if any of these symptoms occur.
Device-related complications: The intracerebroventricular access device used to deliver Brineura may be associated with several complications. These include infections at the device site or within the cerebrospinal fluid (meningitis), device malfunction, device leakage, or device migration. Signs of a possible device-related infection include fever, headache, neck stiffness, sensitivity to light, nausea, vomiting, and altered mental status. Signs of device problems include swelling, redness of the scalp, fluid leakage from the device, and scalp bulging. Treatment may need to be interrupted if the device requires replacement or until infection resolves. Within 4 years of use, the access device may need to be replaced, as determined by the treating physician.
Cardiovascular monitoring: The healthcare team will monitor heart rate, blood pressure, respiratory rate, and temperature before, during, and after each infusion. An electrocardiogram (ECG) will be performed every 6 months to check for abnormal electrical activity in the heart. For patients with a history of heart problems, cardiac monitoring will be performed during every infusion session.
Cerebrospinal fluid monitoring: The treating physician will periodically send samples of cerebrospinal fluid for laboratory analysis to check for signs of infection or other abnormalities, such as elevated protein levels or increased cell counts.
Advanced disease and young children: Brineura has not been studied in patients with signs of advanced CLN2 disease at treatment initiation or in children younger than 2 years of age. There is limited clinical experience in children around 2 years of age. The treating physician will discuss whether Brineura is appropriate based on the individual clinical situation.
The physician may administer antipyretic (fever-reducing) medications and antihistamines before each Brineura infusion to reduce the likelihood and severity of infusion-related reactions that may occur during or shortly after treatment.
Pregnancy and Breastfeeding
Brineura should not be used during pregnancy unless the potential clinical benefit clearly outweighs the potential risk to the unborn child. There are no adequate and well-controlled studies of cerliponase alfa in pregnant women, and it is unknown whether the medication can cause harm to a developing fetus. Women of childbearing potential should discuss family planning with their physician before starting treatment.
It is not known whether cerliponase alfa is excreted in human breast milk. A decision should be made between the treating physician and the patient about whether to discontinue breastfeeding or to discontinue Brineura therapy, taking into account the importance of the treatment for the patient and any potential risks to the nursing infant.
The effects of cerliponase alfa on human fertility have not been studied. There are currently no data available regarding potential impacts on reproductive function.
Each vial of Brineura contains 17.4 mg sodium (corresponding to approximately 0.87% of the WHO-recommended maximum daily sodium intake for adults) and less than 1 mmol (39 mg) potassium, making it essentially potassium-free. These amounts are generally not clinically significant but should be considered in patients on sodium- or potassium-restricted diets.
How Does Brineura Interact with Other Drugs?
Brineura (cerliponase alfa) is a recombinant enzyme that is delivered directly into the cerebrospinal fluid through intracerebroventricular infusion. Unlike systemically administered small-molecule drugs, cerliponase alfa does not undergo hepatic metabolism and is not expected to interact with cytochrome P450 enzymes or other drug-metabolizing pathways. Therefore, the risk of traditional pharmacokinetic drug-drug interactions is considered minimal.
However, there are several important considerations regarding concurrent medication use in patients receiving Brineura:
| Medication Type | Consideration | Recommendation |
|---|---|---|
| Anti-seizure medications | Most CLN2 patients require ongoing epilepsy treatment | Continue as directed; no dose adjustment expected |
| Antipyretics (e.g., paracetamol) | Often given as premedication before infusion | Administer as prescribed to reduce infusion-related fever |
| Antihistamines | Used as premedication to prevent hypersensitivity | Administer as prescribed before each infusion |
| Immunosuppressants | May affect immune response to Brineura | Discuss with physician; monitor for reduced efficacy or increased infection risk |
| Antibiotics | May be needed for device-related infections | Treat infections promptly; Brineura infusion may be delayed |
Patients and caregivers should maintain a complete list of all prescription medications, over-the-counter drugs, vitamins, and herbal supplements being taken and share this information with the healthcare team at every visit. While significant drug interactions are unlikely, comprehensive medication documentation is essential for optimal clinical care, particularly in the context of a complex treatment regimen involving intracerebroventricular drug delivery.
What Is the Correct Dosage of Brineura?
Brineura must be administered by a healthcare professional experienced in intracerebroventricular drug delivery in a hospital or clinical setting. Prior to the first infusion, the patient must undergo a surgical procedure to implant an intracerebroventricular access device (reservoir) that allows the medication to be delivered directly into the brain ventricles. This device remains in place throughout the course of treatment.
Age-Based Dosing
The recommended dose of Brineura is determined by the patient's age and is administered once every two weeks (every 14 days). The following age-based dosing schedule has been established:
| Age Group | Recommended Dose | Notes |
|---|---|---|
| Birth to < 6 months | 100 mg | Limited clinical experience |
| 6 months to < 1 year | 150 mg | Limited clinical experience |
| 1 year to < 2 years | 200 mg (first 4 doses), then 300 mg | Dose escalation after initial 4 doses |
| 2 years and older | 300 mg | Standard maintenance dose |
Infusion Procedure
Brineura is slowly infused through the implanted intracerebroventricular access device. After the full dose of Brineura has been delivered, a flush solution is infused to ensure that all remaining medication in the infusion tubing is delivered to the brain. The total infusion time, including both the medication and the flush solution, typically ranges from approximately 2 to 4.5 hours, depending on the dose being administered.
Before each infusion, the healthcare team will verify proper function of the access device. Vital signs (heart rate, blood pressure, respiratory rate, and temperature) are monitored before, during, and after the infusion. The patient should remain under clinical observation for an appropriate period following each treatment session.
Dose Adjustments
The treating physician may adjust the dosage or infusion rate under the following circumstances:
- Poor tolerance to infusion: If the patient experiences significant symptoms during or after infusion, the rate may be slowed or the dose temporarily reduced.
- Allergic or hypersensitivity reactions: Depending on severity, the infusion may be slowed, temporarily stopped, or permanently discontinued.
- Signs of increased intracranial pressure: If there are clinical indications of elevated pressure within the brain, the physician may modify the infusion parameters accordingly.
Missed Dose
Brineura is administered every two weeks on a fixed schedule in a hospital or clinic setting. If a scheduled infusion is missed (for example, due to illness or device-related complications), the healthcare team will reschedule the treatment as soon as possible. Patients and caregivers should contact their treatment center to arrange the next infusion. The dosing schedule should be resumed at the next scheduled time point; double doses should never be administered to compensate for a missed infusion.
Overdose
There is limited clinical experience with Brineura overdose. In the event that a dose higher than recommended is inadvertently administered, the patient should be closely monitored for any adverse effects, particularly signs of increased intracranial pressure, hypersensitivity reactions, or cardiovascular changes. Treatment would be supportive and directed at specific symptoms. The treating physician should be contacted immediately if an overdose is suspected.
What Are the Side Effects of Brineura?
Clinical trials and post-marketing surveillance have identified several side effects associated with Brineura treatment. Not all patients will experience these effects, and their severity can vary considerably. It is important for patients and caregivers to be aware of potential adverse reactions and to report any concerning symptoms to the healthcare team promptly.
Contact your healthcare provider or seek emergency care immediately if you observe seizures (convulsions), signs of severe allergic reaction (hives, difficulty breathing, swelling of lips or tongue, rapid heartbeat, fainting), or signs of possible device infection (fever with headache, neck stiffness, sensitivity to light, altered mental status).
Very Common Side Effects
May affect more than 1 in 10 patients
- Seizures (convulsions)
- Hypersensitivity reactions during or shortly after infusion (hives, itching, flushing, swollen lips/tongue/throat, breathing difficulties, hoarseness, cyanosis, low muscle tone, fainting, incontinence)
- Fever (pyrexia)
- Vomiting
- Irritability
- Headache
- Increased or decreased protein levels in cerebrospinal fluid (detected by laboratory tests)
- Abnormal ECG (electrocardiogram) findings
- Increased cell count in cerebrospinal fluid (pleocytosis, detected by laboratory tests)
- Upper respiratory tract infection (common cold)
- Needle issues (infusion needle becoming dislodged from the implanted device)
Common Side Effects
May affect up to 1 in 10 patients
- Device-related bacterial infections
- Severe allergic reaction (anaphylaxis)
- Slower heart rate (bradycardia)
- Device malfunction due to blockage (detected during infusion preparation)
- Pain
- Rash
- Hives (urticaria)
- Head drop (chin falling toward chest)
- Abdominal pain
- Device leakage
- Mouth or tongue blisters
- Swelling or redness of eyelids and the white of the eye (conjunctivitis)
- Nervousness
- Gastrointestinal disturbances
Not Known Frequency
Cannot be estimated from available data
- Meningitis (inflammation of the membranes surrounding the brain) due to device-related infection
- Device displacement causing malfunction during infusion preparation
Understanding Device-Related Complications
Because Brineura requires administration through a surgically implanted intracerebroventricular access device, a subset of adverse events is directly related to this device. Device-related complications are among the most clinically significant concerns during long-term Brineura treatment and include infections (both superficial and deep, including meningitis), device malfunction or blockage, needle dislodgement during infusion, device leakage, and device migration requiring surgical revision.
Healthcare teams experienced in managing intracerebroventricular access devices are essential for minimizing these risks. Strict aseptic technique during every infusion is critical. Within approximately 4 years of use, the access device may need to be surgically replaced, as determined by the treating physician based on clinical assessment of device integrity and function.
Immunogenicity
As with all protein-based therapeutics, patients may develop antibodies against cerliponase alfa. In clinical studies, some patients developed anti-drug antibodies (ADAs) in serum and/or cerebrospinal fluid. The clinical significance of these antibodies is not fully understood, but the presence of ADAs did not appear to correlate with reduced efficacy or increased adverse events in the clinical trial population. Patients are monitored for the development of neutralizing antibodies as part of routine clinical care.
It is important to report suspected side effects after the medicine has been authorized. This allows continuous monitoring of the benefit-risk balance. Healthcare professionals and patients can report suspected adverse reactions to their national medicines agency (such as the EMA in Europe, the FDA in the United States, or the MHRA in the United Kingdom).
How Should Brineura Be Stored?
Proper storage of Brineura is critical to maintaining the medication's stability and efficacy. The following storage requirements must be strictly observed by healthcare facilities and pharmacies responsible for handling the product:
- Keep out of sight and reach of children.
- Expiry date: Do not use Brineura after the expiry date printed on the vials and outer packaging (after EXP). The expiry date refers to the last day of the stated month.
- Frozen storage: Store upright in a frozen state at -25°C to -15°C. Keep in the original packaging to protect from light.
- Transport and distribution: Transport and distribute in a frozen state at -85°C to -15°C.
- After thawing: Thawed Brineura and flush solution should be used immediately. The medication should only be withdrawn from unopened vials immediately before use.
- Refrigerated storage (if immediate use is not possible): Unopened vials of thawed Brineura and flush solution may be stored in a refrigerator (2°C to 8°C) and must be used within 24 hours.
- Room temperature stability: Chemical and physical stability during use has been demonstrated for up to 12 hours at room temperature (19°C to 25°C). From a microbiological standpoint, opened vials or medication drawn into syringes should be used immediately.
The healthcare professional or pharmacist is responsible for the proper storage of Brineura and for the appropriate disposal of any unused medication. Brineura should not be used if the solution appears discolored beyond the normal slight yellow tint, or if it contains visible particles other than the occasional thin translucent fibers that are considered normal for this product.
What Does Brineura Contain?
Active Ingredient
The active substance in Brineura is cerliponase alfa, a recombinant form of human tripeptidyl peptidase 1 (rhTPP1). Each vial contains 150 mg of cerliponase alfa in 5 mL of solution for infusion, corresponding to a concentration of 30 mg/mL.
Inactive Ingredients (Excipients)
The other ingredients in both the Brineura infusion solution and the flush solution are:
- Sodium phosphate dibasic heptahydrate
- Sodium dihydrogen phosphate monohydrate
- Sodium chloride
- Potassium chloride
- Magnesium chloride hexahydrate
- Calcium chloride dihydrate
- Water for injections
The excipient composition is designed to create a solution with an ionic composition similar to cerebrospinal fluid, ensuring compatibility with the intracerebroventricular route of administration.
Appearance and Packaging
The Brineura infusion solution is a clear to slightly opalescent, colorless to slightly yellow liquid. It may occasionally contain thin translucent fibers or opaque particles, which is considered normal for this type of protein-based biologic product. The flush solution is clear and colorless.
Each package contains two vials of Brineura infusion solution and one vial of flush solution. Every vial contains 5 mL of solution. The marketing authorization holder and manufacturer is BioMarin International Limited, Shanbally, Ringaskiddy, County Cork, Ireland.
Brineura has been authorized under "exceptional circumstances" because, due to the extreme rarity of CLN2 disease, it has not been possible to obtain complete clinical information according to standard regulatory requirements. The European Medicines Agency (EMA) reviews all new information that becomes available annually and updates the product information as necessary. This regulatory status is common for treatments of ultra-rare diseases where large-scale clinical trials are not feasible.
Frequently Asked Questions About Brineura
CLN2 disease (neuronal ceroid lipofuscinosis type 2), also known as late infantile neuronal ceroid lipofuscinosis or TPP1 deficiency, is a rare autosomal recessive genetic disorder. It is caused by mutations in the CLN2/TPP1 gene, leading to a deficiency of the enzyme tripeptidyl peptidase 1 (TPP1). Without functional TPP1, waste materials accumulate in brain cells, causing progressive neurodegeneration. Symptoms typically begin between ages 2 and 4 with seizures, followed by loss of motor function, language, and vision. CLN2 disease is estimated to affect approximately 1 in 100,000 to 200,000 live births worldwide. It affects boys and girls equally.
The intracerebroventricular access device is surgically implanted by a neurosurgeon under general anesthesia. The device consists of a small reservoir placed beneath the scalp, connected to a catheter that extends into one of the brain's ventricles (fluid-filled spaces). This procedure is performed before the first Brineura infusion and typically requires a brief hospital stay. The device allows healthcare professionals to deliver medication directly into the cerebrospinal fluid at each biweekly infusion without the need for repeated surgery. The device may need to be replaced approximately every 4 years or sooner if complications arise.
In the pivotal clinical trial published in the New England Journal of Medicine (Schulz et al., 2018), Brineura demonstrated significant efficacy in slowing the decline of motor and language function compared to a matched untreated historical control group. Treated patients experienced a substantially slower rate of decline on the CLN2 Clinical Rating Scale (a standardized measure of motor and language ability) over 48 weeks. While Brineura does not cure CLN2 disease or reverse existing damage, it meaningfully preserves function and extends the period of independent mobility and communication. Long-term extension studies have continued to show sustained benefits over multiple years of treatment.
Brineura was initially studied in children with CLN2 disease, as the condition predominantly affects pediatric patients. In the original clinical trial, participants were children up to 8 years of age. However, the approved indication covers patients with CLN2 disease without a specific upper age limit. The treating physician will assess whether Brineura is appropriate for individual patients, including older children and young adults, based on their disease status and clinical presentation. Patients with signs of very advanced disease may not be suitable candidates, as the benefits of treatment in advanced stages have not been established.
If Brineura treatment is temporarily interrupted (for example, due to illness, device complications, or logistical reasons), it is important to resume treatment as soon as the interruption is resolved. CLN2 disease is a progressive condition, and extended gaps in therapy may allow disease progression to continue. The biweekly dosing schedule should be resumed at the next practical opportunity. Patients and caregivers should contact their treatment center promptly to reschedule any missed infusions. The treating physician will determine if any dose adjustments are needed upon resumption.
No, Brineura is not a cure for CLN2 disease. It is an enzyme replacement therapy that slows the progression of neurological decline by replacing the missing TPP1 enzyme. While it significantly preserves motor and language function compared to untreated patients, it does not reverse existing neurological damage or halt disease progression entirely. Research into potential curative approaches for CLN2 disease, including gene therapy, is actively ongoing. Brineura represents the current standard of care and provides meaningful clinical benefit, but lifelong treatment is required to maintain its effects.
References
- European Medicines Agency (EMA). Brineura (cerliponase alfa) – Summary of Product Characteristics. Last updated 2022. Available from: EMA – Brineura EPAR.
- U.S. Food and Drug Administration (FDA). Brineura (cerliponase alfa) – Prescribing Information. Approved April 2017, updated 2024. Available from: FDA – Brineura Label.
- Schulz A, Ajayi T, Specchio N, et al. Study of Intraventricular Cerliponase Alfa for CLN2 Disease. New England Journal of Medicine. 2018;378(20):1898-1907. doi:10.1056/NEJMoa1712649.
- Mole SE, Cotman SL. Genetics of the neuronal ceroid lipofuscinoses (Batten disease). Biochimica et Biophysica Acta. 2015;1852(10 Pt B):2237-2241. doi:10.1016/j.bbadis.2015.05.011.
- Williams RE, Adams HR, Blohm M, et al. Management Strategies for CLN2 Disease. Pediatric Neurology. 2017;69:102-112. doi:10.1016/j.pediatrneurol.2017.01.034.
- Nickel M, Simonati A, Jacoby D, et al. Disease characteristics of patients with neuronal ceroid lipofuscinosis type 2 (CLN2): a natural history cohort study. The Lancet Child & Adolescent Health. 2018;2(8):582-590. doi:10.1016/S2352-4642(18)30179-2.
- World Health Organization (WHO). WHO Model List of Essential Medicines for Children. 9th List, 2023. Geneva: World Health Organization.
- BioMarin International Limited. Brineura Patient Information Leaflet. County Cork, Ireland. Last revised 2022.
Medical Editorial Team
Medical Content
Written by iMedic Medical Editorial Team – Specialists in Neurology, Pediatrics, and Rare Diseases
Medical Review
Reviewed by iMedic Medical Review Board according to international guidelines (WHO, EMA, FDA)
Evidence Standard
All medical claims follow GRADE evidence framework. Evidence Level 1A based on randomized controlled trials and systematic reviews.
Editorial Independence
No commercial funding or pharmaceutical sponsorship. Independent medical editorial content with strict conflict-of-interest policies.
Last medical review: | Published: